The role of monoamines in the actions of established and "novel" antidepressant agents: A critical review

European Journal of Pharmacology

Volumn 500, Issue 1-3 SPEC. ISS., 2004, Pages 371-384

  Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Antidepressant; Depression; Dopamine; Monoamine; Neurogenesis; SSRI; Tricyclic

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; AUTORECEPTOR; BETA ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; ENZYME; GLUCOCORTICOID RECEPTOR ANTAGONIST; IMIPRAMINE; IONOTROPIC RECEPTOR ANTAGONIST; LIGAND; MIANSERIN; MIRTAZAPINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROKININ 1 RECEPTOR ANTAGONIST; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AFFECT; APPETITE; AVERSION; BRAIN CORTEX; CATABOLISM; COGNITION; CONVULSION; DEPRESSION; DEVELOPMENT; DISEASE CONTROL; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TARGETING; ENVIRONMENT; ENZYME SYNTHESIS; GENE EXPRESSION; GENE SEQUENCE; GENOMICS; HEREDITY; HORMONE RELEASE; HUMAN; INSOMNIA; LIMBIC SYSTEM; METABOLIC DISORDER; MONOAMINERGIC SYSTEM; MOOD; MOTOR PERFORMANCE; NAUSEA; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NERVOUSNESS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SLEEP DEPRIVATION; SOMNOLENCE; STIMULUS; SYMPTOMATOLOGY; SYNAPSE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER; HUMANS;

EID: 4644353199     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.038     Document Type: Review

References (122)

1. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J. Affect. Disord. 58 2000 19 36
2. V. Andreoli, V. Caillard, R.S. Deo, J.K. Rybakowski, and M. Versiani Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression J. Clin. Psychiatry 22 2002 393 399
3. J.A. Ascher, J.O. Cole, J.N. Colin, J.P. Feighner, R.M. Ferris, H.C. Fibiger, R.N. Golden, P. Martin, W.Z. Potter, and E. Richelson Bupropion: a review of its mechanism of antidepressant activity J. Clin. Psychiatry 56 1995 395 401
4. F. Bai, M. Bergeron, and D.L. Nelson Chronic α-amino-2,3-dihydro-5- methyl-3-oxo-4-isoxazolepropanoic acid receptor potentiator (LY451646) increases cell proliferation in adult rat hippocampus Neuropharmacology 44 2003 1013 1121
5. 1A receptor agonistic properties Eur. J. Pharmacol. 464 1997 127 133
6. J.K. Belanoff, B.H. Flores, M. Kalezhan, B. Sund, and A.F. Schatzberg Rapid reversal of psychotic depression using mifepristone J. Clin. Psychopharmacol. 21 2001 516 521
7. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depression Biol. Psychiatry 47 2000 351 354
8. 1 adrenergic receptor subtypes in discrete regions of rat brain J. Neurosci. 10 1990 2580 2586
9. P. Blier The pharmacology of putative early-onset antidepressant strategies Eur. NeuroPsychopharmacol. 13 2003 57 66
10. F. Borsini, K. Evans, K. Jason, F. Rohde, B. Alexander, and S. Pollentier Pharmacology of flibanserin CNS Drug Rev. 8 2002 117
11. F.P. Bymaster, R.K. McNamara, and P.V. Tran New approaches to developing antidepressants by enhancing monoaminergic transmission Expert Opin. Investig. Drugs 12 2003 531 543
12. G.B. Cassano, and M.C. Jori Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study Int. Clin. Psychopharmacol. 17 2002 27 32
13. 2)-adrenoceptor antagonist and monoamine uptake inhibitor properties J. Med. Chem. 44 2001 787 805
14. M.H. Corrigan, A.Q. Denahan, C.E. Wright, R.J. Ragual, and D.L. Evans Comparison of pramipexole, fluoxetine, and placebo in patients with major depression Depress. Anxiety 11 2000 58 65
15. A.M. Crissman, and J.M. O'Donnell Effects of antidepressants in rats trained to discriminative centrally administered isoproterenol J. Pharmacol. Exp. Ther. 302 2002 606 611
16. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol. Sci. 23 2002 238 245
17. R.J. Davidson, W. Irwin, M.J. Anderle, and N.H. Kalin The neural substrates of affective processing in depressed patients treated with venlafaxine Am. J. Psychiatry 160 2003 64 75
18. R. Davis, R. Whittington, and H.M. Bryson Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression Drugs 53 1997 608 636
19. P.L. Delgado Depression: the case for monoamine deficiency J. Clin. Psychiatry 61 2000 7 11
20. 2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex J. Neurochem. 88 2004 1003 1009
21. P. Devoto, G. Flore, L. Pira, G. Longu, and G.L. Gessa Mirtazapine-induced co-release of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex Eur. J. Pharmacol. 487 2004 105 1110
22. 2 receptors Curr. Neuropharmacol. 1 2003 153 164
23. R.J. Donati, and M.M. Rasenick G-protein signalling and the molecular basis of antidepressant action Life Sci. 73 2003 1 17
24. 2A changes persist after chronic stress Eur. J. Neurosci. 17 2003 917 928
25. 1B receptors Neuropsychopharmacology 21 1999 268 284
26. P.W. Gold, and G.P. Chrousos Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states Mol. Psychiatry 7 2002 254 275
27. P.E. Greenberg, R.C. Kessler, H.G. Birnbaum, S.A. Leong, S.W. Lowe, P.A. Berglund, and P.K. Corey-Lisle The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64 2003 1465 1475
28. S.J.A. Grove, G.A. Rogers, and M.Q. Zhang Positive modulators of the α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid receptor Expert Opin. Ther. Pat. 10 2000 1539 1548
29. Gründer, G., Wetzel, H., Hammes, E., Benkert, O., Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology. 111, 123-126.
30. 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice J. Neurochem. 89 2004 54 63
31. S.E. Hammack, M.J. Schmid, M. LoPresti, A. Der-Avakian, M.A. Pellymounter, A.C. Foster, L.R. Watkins, and S.F. Maier Corticotropin releasing hormone type 2 receptors in dorsal raphe nucleus mediate the behavioural consequences of stress J. Neurosci. 23 2003 1019 1025
32. O.J. Hoyberg, G. Wik, O.P. Mehtonen, B.W.M.M. Peeters, and C. Sennef Org 34517, a selective glucocortical receptor antagonist with potent antidepressant activity. First clinical results Int. J. Neuropsychopharmacol. 5 2002 P.3.E.044
33. C.-J. Hong, and S.-J. Tsai Genomic approaches to depression Curr. Pharmacogen. 1 2003 67 74
34. 1B) antagonist J. Pharmacol. Exp. Ther. 304 2003 1072
35. B.L. Jacobs, H. Praag, and F.H. Gage Adult brain neurogenesis and psychiatry: a novel theory of depression Mol. Psychiatry 5 2000 262 269
36. 3 receptors as a therapeutic target for antipsychotic and antiparkinsonian drugs Pharmacol. Ther. 90 2001 231 259
37. S. Kasper Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data Int. Clin. Psychopharmacol. 10 1995 25 35
38. G.G. Kinney, M.T. Taber, and V.K. Gribkoff The augmentation hypothesis for improvement of antidepressant therapy Mol. Neurobiol. 21 2000 137 154
39. S. Kitayama, and T. Dohi Norepinephrine transporter splice variants and their interaction with substrates and blockers Eur. J. Pharmacol. 479 2003 65 70
40. 3-immunoreactive neurones in serotonergic cell groups in the rat brain Neurosci. Lett. 323 2002 146 150
41. E. Lehr Potential antidepressant properties of pramipexole detected in locomotor and operant behavioural investigation in mice Psychopharmacology 163 2002 495 500
42. 1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study Brain Res. 935 2002 134 139
43. B. Lerer, and F. Macciardi Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions Int. J. Neuropsychopharmacol. 8 2002 255 275
44. 2 receptors Curr. Drug Targets 3 2004 11 26
45. X. Li, J.M. Witkin, A.B. Need, and P. Skolnick Enhancement of antidepressant potency by a potentiator of α-amino-2,3-dihydro-5-methyl-3- oxo-4-isoxazolepropanoic acid receptors Cell. Mol. Neurobiol. 23 2003 419 430
46. 2C antagonist, in the treatment of major depressive disorder. A placebo controlled dose range study Int. Clin. Psychopharmacol. 17 2002 239 247
47. I. Lucki, A. Singh, and D.S. Kreiss Antidepressant-like behavioral effects of serotonin receptor agonists Neurosci. Biobehav. Rev. 18 1994 85 95
48. M. Mackowiak, M. O'Neill, M. Hicks, D. Bleakman, and P. Skolnick An α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid receptor potentiator modulates hippocampal expression of brain-derived neurotrophic factor Neuropharmacology 43 2002 1 10
49. J.E. Malberg, and R.S. Duman Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment Neuropsychopharmacology 28 2003 1562 1571
50. H.K. Manji, J.A. Quiroz, J. Sporn, J.L. Payne, K. Denicoff, N.A. Gray, C.A. Zarate, and D.S. Charney Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression Biol. Psychiatry 53 2003 707 742
51. K.A. Maubach, N.M.J. Rupniak, M.S. Kramer, and R.G. Hill Novel strategies for pharmacotherapy of depression Curr. Opin. Chem. Biol. 3 1999 481 488
52. 1 receptors: function, behavioral consequences and therapeutic opportunities Brain Res. Rev. 37 2001 116 132
53. 1B receptor mutant mice J. Pharmacol. Exp. Ther. 298 2001 1101 1107
54. B.S. McEwen Effects of adverse experiences for brain structure and function Biol. Psychiatry 48 2000 721 731
55. M.J. Millan The neurobiology and control of anxious states Prog. Neurobiol. 70 2003 83 244
56. 1C/2 antagonists as therapeutic agents Drug News Perspect. 5 1992 397 406
57. 2C receptors: a comparison with citalopram Eur. J. Neurosci. 12 2000 1079 1095
58. M.J. Millan, F. Lejeune, and A. Gobert Reciprocal autoreceptor and heteroceptor control of serotonergic, dopaminergic and adrenergic transmission in frontal cortex: a review, and relevance to the actions of antidepressant agents J. Psychopharmacol. 14 2000 114 138
59. M.J. Millan, A. Gobert, F. Lejeune, A. Newman-Tancredi, J.-M. Rivet, A. Auclair, and J.-L. Peglion S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine J. Pharmacol. Exp. Ther. 298 2001 565 580
60. 1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats J. Neurochem. 76 2001 1949 1954
61. 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways J. Pharmacol. Exp. Ther. 306 2003 954 964
62. 2C receptor blockade Psychopharmacology 2004 (in press)
63. 2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison to ropinirole J. Pharmacol. Exp. Ther. 309 2004 162 175
64. 1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat Eur. J. Pharmacol. 432 2001 19 27
65. S.A. Montgomery, D.S. Baldwin, and A. Riley Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction J. Affect. Disord. 69 2002 119 140
66. -1 receptor gene knockout mice Eur. J. Neurosci. 18 2003 1828 1836
67. 1A-adrenoceptor mRNA level in rat prefrontal cortex Eur. J. Pharmacol. 444 2002 151 159
68. C.A. Naranjo, L.K. Tremblay, and U.E. Busto The role of the brain reward system in depression Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 2001 781 823
69. M. Naughton, J.B. Mulrooney, and B.E. Leonard A review of the role of serotonin receptors in psychiatric disorders Hum. Psychopharm. Clin. Exp. 15 2000 397 415
70. 5 receptors Curr. Drug Targets 3 2004 53 58
71. S.S. Newton, J. Thome, T.L. Wallace, Y. Shirayama, L. Schlesinger, N. Sakai, J. Chen, R. Neve, E.J. Nestler, and R.S. Duman Inhibition of cAMP or dynorphin in the nucleus accumbens produces an antidepressant-like effect J. Neurosci. 24 2002 10883 10890
72. P.V. Nguyen, and N.H. Woo Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases Prog. Neurobiol. 71 2003 401 437
73. 2-Adrenoceptors and depression J. Psychopharmacol. 10 1996 35 42
74. J.M. O'Donnell, and H.-T. Zhang Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4) Trends Pharmacol. Sci. 25 2004 158 163
75. 2-adrenoceptors in locus coeruleus in depression Biol. Psychiatry 53 2003 315 323
76. P. Pacher, E. Kohegyi, V. Kecskemeti, and S. Furst Current trends in the development of new antidepressants Curr. Med. Chem. 8 2001 89 100
77. C.M. Padovan, and F.S. Guimaraes Antidepressant-like effects of NMDA receptor antagonists injected into the dorsal hippocampus of rats Pharmacol. Biochem. Behav. 77 2004 15 19
78. 3 tachykinin receptor agonist aminosenktide in mouse lines differing in endogenous opioid system activity Peptides 22 2001 1037 1042
79. J.L. Payne, J.A. Quiroz, C.A. Zarate, and H.K. Manji Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol. Psychiatry 52 2002 921 926
80. Q. Pei, T.S.C. Zetterström, M. Sprakes, R. Tordera, and T. Sharp Antidepressant drug treatment induces Arc gene expression in the rat brain Neuroscience 121 2003 975 982
81. 2 agonist-induced Arc gene expression in the rat cortex Neuropharmacology 46 2004 331 339
82. V. Perez, D. Puigdemont, I. Gilaberte, E. Alvarez, and F. Artigas Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors J. Clin. Psychopharmacol. 21 2001 36 45
83. R.B. Raffa Possible roles of neurokinins in central nervous system development and neurodegenerative or other disorders Neurosci. Biobehav. Rev. 22 1998 789 813
84. L.P. Reagan, D.R. Rosell, G.E. Wood, M. Spedding, C. Munoz, J. Rothstein, and B.S. McEwen Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine PNAS 101 2004 2179 2184
85. J.M. Reul, and F. Holsboer Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression Curr. Opin. Pharmacol. 2 2002 23 33
86. V.I. Reus, and O.M. Wolkowitz Antiglucocorticoid drugs in the treatment of depression Exp. Opin. Invest. 10 2001 1789 1796
87. Z. Rogoz, G. Skuza, J. Maj, and W. Danysz Synergistic effect of uncompetitive N-methyl-d-aspartate receptor antagonists and antidepressant drugs in the forced swimming test in rats Neuropharmacology 42 2002 1024 1030
88. H. Rollema, T. Clarke, Y. Lu, A. Schmidt, and J. Sprouse Comparison of the effects of CP-93,393 and buspirone on 5-HAT and NE release: microdialysis studies in the hippocampus of freely moving rats and guinea pigs J. Neurochem. 66 1996 S37
89. B.L. Roth, D.J. Sheffler, and W.K. Kroeze Magic shotguns vs. magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev., Drug Discov. 3 2004 353 359
90. 1 receptor) antagonists Curr. Opin. Investig. Drugs 3 2002 257 261
91. 1 piperazine derivatives Bioorg. Med. Chem. Lett. 12 2002 3195 3198
92. 2-adrenoceptor subtype C in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels Mol. Psychiatry 4 1998 443 452
93. C. Sanchez, and J. Hyttel Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding Cell. Mol. Neurobiol. 19 1999 467 489
94. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, S. Dulawa, N. Weisstaub, J. Lee, R. Duman, O. Arancio, C. Belzung, and R. Hen Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805 809
95. A.F. Schatzberg Pharmacological principles of antidepressant efficacy Hum. Psychopharmacol. 17 2002 S17 S22
96. P. Schmitt, V. Reny-Palasse, O. Bourde, C. Garcia, and J.F. Pujol Further characterization of the long-term effect of RU24722 on tyrosine hydroxylase in the rat locus coeruleus J. Neurochem. 61 1993 1423 1429
97. 2A- adrenergic receptor plays a protective role in mouse models of depression and anxiety J. Neurosci. 21 2001 4875 4882
98. R.C. Shelton, G.D. Tollefson, M. Tohen, S. Stahl, K.S. Gannon, T.G. Jacobs, W.R. Buras, F.P. Bymaster, W. Zhang, K.A. Spencer, P.D. Feldman, and H.Y. Meltzer A novel augmentation strategy for treating resistant major depression Am. J. Psychiatry 158 2001 131 134
99. Y. Shirayama, A.C.-H. Chen, S. Nakagawa, D.S. Russell, and R.S. Duman BDNF produces antidepressant effects in behavioural models of depression J. Neurosci. 22 2002 3251 3261
100. E. Shorter, and P. Tyrer Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease Br. Med. J. 327 2003 158 160
101. P. Skolnick, B. Legutko, X. Li, and F.P. Bymaster Current perspectives on the development of non-biogenic amine-based antidepressants Pharmacol. Res. 43 2001 411 443
102. L.A. Sorbera, P. Leeson, and J. Castaner Robalzotan tartrate hydrate Drugs Future 24 1999 740
103. 2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function J. Pharmacol. Exp. Ther. 299 2001 449 458
104. 1- adrenergic system that regulates behavioral activation and is impaired in depression Neuropsychopharmacology 28 2003 1387 1399
105. P. Svenningsson, E.T. Tzavara, J. Witkin, A.A. Fienberg, G.G. Nomikos, and P. Greengard Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Proc. Natl. Acad. Sci. 99 2002 3182 3187
106. C.A. Tamminga, C.B. Nemeroff, R.D. Blakely, L. Brady, C.S. Carter, K.L. Davis, R. Dingledine, J.M. Gorman, D.E. Grigoriadis, D.C. Henderson, R.B. Innis, J. Killen, T.P. Laughren, W.M. McDonald, G.M. Murphy, S.M. Paul, M.V. Rudorfer, E. Sausville, A.F. Schatzberg, E.M. Scolnick, and T. Suppes Developing novel treatments for mood disorders: accelerating discovery Biol. Psychiatry 52 2002 589 609
107. 7 receptors Curr. Drug Targets 3 2004 81 90
108. G.E. Torres, R.R. Gainetdinov, and M.G. Caron Plasma membrane monoamine transporters: structure, regulation and function Nat. Rev., Neurosci. 4 2003 13 25
109. 1A receptor agonist OPC-14523 Neuropharmacology 41 2001 976 988
110. 1 receptor agonist igmesine involves modulation of intracellular calcium mobilization Psychopharmacology 163 2002 26 35
111. M.G.C. Van der Hart, B. Czéh, G. De Biurrun, T. Michaelis, T. Watanabe, O. Natt, J. Frahm, and E. Fuchs Substance P antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis and hippocampal volume Mol. Psychiatry 7 2002 933 941
112. J. Vetulani, and I. Nalepa Antidepressants: past, present and future Eur. J. Pharmacol. 405 2000 351 363
113. S. Vida, and K. Cooper Precision and comparability of adverse event rates of newer antidepressants J. Clin. Psychopharmacol. 19 1999 416 426
114. D.J. Walker, J.U. Peter, S. Bashammakh, H. Hortnagl, M. Voits, H. Fink, and M. Bader Synthesis of serotonin by a second tryptophan hydroxylase isoform Science 299 2003 76 78
115. M.-L. Wong, and J. Licinio From monoamines to genomic targets: a paradigm shift for drug discovery in depression Nat. Rev., Neurosci. 3 2004 136 151
116. 6 receptors Curr. Drug Targets 3 2004 59 79
117. 1A receptor antagonist NAD-299. Results from an 8 week placebo and paroxetine-controlled study Eur. Neuropsychopharmacol. 13 2003 S189
118. J.M. Zajecka Treating depression to remission J. Clin. Psychiatry 64 2003 7 12
119. C. Zarate, J. Quiroz, J. Payne, and H. Manji Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders Psychopharmacol. Bull. 36 2003 35 83
120. H.-T. Zhang, Y. Huang, S.L.C. Jin, S.A. Frith, M.S. Neesha Suvarna, M. Conti, and J.M. O'Donnell Antidepressant-like profile and reduced sensitivity to Rolipram in mice deficient in the PDE4D phosphodiesterase enzyme Neuropsychopharmacology 27 2002 587 595
121. H.-T. Zhang, Y. Huang, and J.M. O'Donnell Antagonism of the antidepressant-like effects of clenbuterol by central administration of β-adrenergic antagonists in rats Psychopharmacology 170 2003 102 107
122. 1 antagonist, R121919, in major depression: the first 20 patients treated J. Psychiat. Res. 34 2000 181 717